Immediate Impact
28 standout
Citing Papers
Antibody–Drug Conjugates (ADCs): current and future biopharmaceuticals
2025 Standout
Effective extracellular payload release and immunomodulatory interactions govern the therapeutic effect of trastuzumab deruxtecan (T-DXd)
2025 Standout
Works of Asma Dilawari being referenced
US Food and Drug Administration Approval Summary: Fam-Trastuzumab Deruxtecan-nxki for Human Epidermal Growth Factor Receptor 2-Low Unresectable or Metastatic Breast Cancer
2023
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Asma Dilawari | 141 | 46 | 40 | 28 | 234 | |
| Ahmet Serkan İlgün | 179 | 47 | 41 | 27 | 293 | |
| Asim Jamal Shaikh | 131 | 52 | 39 | 38 | 285 | |
| Mohammad Houshyari | 122 | 36 | 29 | 35 | 294 | |
| Deena Graham | 100 | 71 | 32 | 25 | 233 | |
| Razan Mansour | 82 | 28 | 21 | 34 | 256 | |
| Kimberly A. Herget | 124 | 53 | 28 | 23 | 280 | |
| Amanda R. Kahl | 154 | 37 | 25 | 33 | 263 | |
| Leigh Boehmer | 92 | 62 | 17 | 41 | 238 | |
| Alexandra Bukowski | 128 | 17 | 34 | 22 | 283 | |
| Gilberto Morgan‐Villela | 106 | 19 | 39 | 27 | 292 |
All Works
Login with ORCID to disown or claim papers
Loading papers...